PATENT CLAIM ANALYSIS

Application Number: 15750425
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["424", "139100"]

Abstract:
Anti-CD122 and/or γc antibodies and fragments thereof are disclosed. Also disclosed are compositions comprising such antibodies and fragments, and uses and methods using the same.

Claim (Index 88):
A method of treating cancer, an infectious disease or a T cell dysfunctional disorder comprising administering an antibody or antigen binding fragment to a patient suffering from a cancer, an infectious disease or a T cell dysfunctional disorder, wherein the antibody or antigen binding fragment is capable of binding to CD122 and common \u03b3 chain (\u03b3c), and wherein the antibody or antigen binding fragment is an IL-2 receptor agonist.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 88.0
- Lexical Diversity: 1.4
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15229336', '15495048', '15486468', '15521685', '15521434']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.743118450275628
- 35 USC 102 Novelty (BERT): 0.7185024488485495
- Combined Prediction Score: 0.74065685013292
- Mean Citation Score: 532.3024059999998
- Max Citation Score: 948.52997
- Similarity Product: 747.2787221028237

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test